

Robert C Schuit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4771203/publications.pdf>

Version: 2024-02-01

52
papers

1,045
citations

394421

19
h-index

454955

30
g-index

53
all docs

53
docs citations

53
times ranked

1827
citing authors

#	ARTICLE	IF	CITATIONS
1	Parametric methods for [¹⁸ F]flortaucipir PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 365-373.	4.3	22
2	PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [¹¹ C]SMW139. <i>Journal of Neuroinflammation</i> , 2020, 17, 300.	7.2	15
3	¹¹ C-sorafenib and ¹⁵ O-H ₂ O PET for early evaluation of sorafenib therapy. <i>Journal of Nuclear Medicine</i> , 2020, 62, jnumed.120.251611.	5.0	0
4	Effect of the monoaminergic stabiliser (α ²)-OSU6162 on mental fatigue following stroke or traumatic brain injury. <i>Acta Neuropsychiatrica</i> , 2020, 32, 303-312.	2.1	7
5	Quantification of [¹⁸ F]florbetapir: A test-retest tracer kinetic modelling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2172-2180.	4.3	22
6	Evaluation of the Novel PET Tracer [¹¹ C]HACH242 for Imaging the GluN2B NMDA Receptor in Non-Human Primates. <i>Molecular Imaging and Biology</i> , 2019, 21, 676-685.	2.6	8
7	Identification of the allosteric P2X7 receptor antagonist [¹¹ C]SMW139 as a PET tracer of microglial activation. <i>Scientific Reports</i> , 2018, 8, 6580.	3.3	54
8	P3-438: PARAMETRIC IMAGING OF [¹⁸ F]FLORBETAPIR: A TEST-RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1281.	0.8	0
9	First in human evaluation of [¹⁸ F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors. <i>EJNMMI Research</i> , 2018, 8, 69.	2.5	9
10	Quantification of O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine kinetics in glioma. <i>EJNMMI Research</i> , 2018, 8, 72.	2.5	14
11	Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([¹⁸ F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2018, 3, 11.	3.9	4
12	In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model. <i>EJNMMI Research</i> , 2018, 8, 39.	2.5	5
13	A novel partial volume correction method for accurate quantification of [¹⁸ F] flortaucipir in the hippocampus. <i>EJNMMI Research</i> , 2018, 8, 79.	2.5	19
14	Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P ₁₋₇ . <i>Molecular Pharmaceutics</i> , 2018, 15, 4872-4883.	4.6	1
15	Open study with (α ²)-OSU6162 in multiple sclerosis-related fatigue. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 482-489.	2.1	8
16	Altered GABA _A receptor density and unaltered blood-brain barrier [¹¹ C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 97-105.	4.3	8
17	Quantification of Tau Load Using [¹⁸ F]AV1451 PET. <i>Molecular Imaging and Biology</i> , 2017, 19, 963-971.	2.6	42
18	Synthesis, radiolabeling and preclinical evaluation of a [¹¹ C]GMOM derivative as PET radiotracer for the ion channel of the N-methyl-D-aspartate receptor. <i>Nuclear Medicine and Biology</i> , 2017, 51, 25-32.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Human Dosimetry of the ¹¹ C-Methyl-d-Aspartate Receptor Ligand ¹¹ C-GMOM. Journal of Nuclear Medicine, 2017, 58, 1330-1333.	5.0	2
20	Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier. ACS Chemical Neuroscience, 2017, 8, 1925-1936.	3.5	8
21	Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase. Nuclear Medicine and Biology, 2017, 44, 90-104.	0.6	8
22	[²³ Al]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORAUICIPIR. Alzheimer's and Dementia, 2017, 13, P1364.	0.8	0
23	[²⁰ Al]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORAUICIPIR. Alzheimer's and Dementia, 2017, 13, P150.	0.8	0
24	Development of [¹¹ C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts. Oncotarget, 2017, 8, 38337-38350.	1.8	7
25	[¹⁸ F]AV-1451: Quantification of TAU Load Using [¹⁸ F]AV-1451 and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.8	0
26	[¹⁸ F]AV-1451: Quantification of Tau Load Using [¹⁸ F]AV-1451 and Pet. Alzheimer's and Dementia, 2016, 12, P1109.	0.8	0
27	Two anti-angiogenic TKI-PET tracers, [¹¹ C]axitinib and [¹¹ C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents. Nuclear Medicine and Biology, 2016, 43, 612-624.	0.6	11
28	Noninvasive Quantification of Myocardial ¹¹ C-Meta-Hydroxyephedrine Kinetics. Journal of Nuclear Medicine, 2016, 57, 1376-1381.	5.0	12
29	Parametric Binding Images of the TSPO Ligand ¹⁸ F-DPA-714. Journal of Nuclear Medicine, 2016, 57, 1543-1547.	5.0	23
30	Synthesis, radiolabeling and evaluation of novel amine guanidine derivatives as potential positron emission tomography tracers for the ion channel of the N-methyl-d-aspartate receptor. European Journal of Medicinal Chemistry, 2016, 118, 143-160.	5.5	10
31	Impact of New Scatter Correction Strategies on High-Resolution Research Tomograph Brain PET Studies. Molecular Imaging and Biology, 2016, 18, 627-635.	2.6	3
32	Effects of erlotinib therapy on [¹¹ C]erlotinib uptake in EGFR mutated, advanced NSCLC. EJNMMI Research, 2016, 6, 10.	2.5	30
33	Quantification of the novel ¹¹ C-methyl-d-aspartate receptor ligand [¹¹ C]GMOM in man. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1111-1121.	4.3	19
34	Quantitative and Simplified Analysis of ¹¹ C-Erlotinib Studies. Journal of Nuclear Medicine, 2016, 57, 861-866.	5.0	22
35	Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase. Nuclear Medicine and Biology, 2016, 43, 232-242.	0.6	29
36	Quantification of ¹¹ C-Laniquidar Kinetics in the Brain. Journal of Nuclear Medicine, 2015, 56, 1730-1735.	5.0	5

#	ARTICLE	IF	CITATIONS
37	Preclinical evaluation of [¹⁸ F]PK-209, a new PET ligand for imaging the ion-channel site of NMDA receptors. <i>Nuclear Medicine and Biology</i> , 2015, 42, 205-212.	0.6	21
38	Synthesis, structure activity relationship, radiolabeling and preclinical evaluation of high affinity ligands for the ion channel of the N-methyl-d-aspartate receptor as potential imaging probes for positron emission tomography. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1189-1206.	3.0	14
39	Quantification of ¹⁸ F-Fluorocholine Kinetics in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 365-371.	5.0	32
40	[¹⁸ F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models. <i>Molecular Imaging and Biology</i> , 2015, 17, 615-619.	2.6	40
41	The Dopamine Stabilizer (α)-OSU6162 Occupies a Subpopulation of Striatal Dopamine D2/D3 Receptors: An [¹¹ C]Raclopride PET Study in Healthy Human Subjects. <i>Neuropsychopharmacology</i> , 2015, 40, 472-479.	5.4	22
42	Quantification of [¹⁸ F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer'S Disease Patients. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 766-772.	4.3	99
43	Use of a Single ¹¹ C-Meta-Hydroxyephedrine Scan for Assessing Flow-Innervation Mismatches in Patients with Ischemic Cardiomyopathy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1706-1711.	5.0	27
44	⁸⁹ Zr-cetuximab PET imaging in patients with advanced colorectal cancer. <i>Oncotarget</i> , 2015, 6, 30384-30393.	1.8	106
45	Parametric Methods for Quantification of ¹⁸ F-FAZA Kinetics in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1772-1777.	5.0	12
46	Assessment of Simplified Methods to Measure ¹⁸ F-FLT Uptake Changes in EGFR-Mutated Non-Small Cell Lung Cancer Patients Undergoing EGFR Tyrosine Kinase Inhibitor Treatment. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1417-1423.	5.0	17
47	Development of [¹⁸ F]afatinib as new TKI-PET tracer for EGFR positive tumors. <i>Nuclear Medicine and Biology</i> , 2014, 41, 749-757.	0.6	39
48	Synthesis and preclinical evaluation of carbon-11 labelled N-((5-(4-fluoro-2-[¹¹ C]methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamine as a PET tracer for NR2B subunit-containing NMDA receptors. <i>Nuclear Medicine and Biology</i> , 2014, 41, 670-680.	0.6	15
49	ImmunoPET imaging with ⁸⁹ Zr-cetuximab in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11102-11102.	1.6	2
50	[¹¹ C]Sorafenib: Radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer. <i>Nuclear Medicine and Biology</i> , 2013, 40, 488-497.	0.6	24
51	Development of [¹¹ C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status. <i>Clinical Cancer Research</i> , 2013, 19, 183-193.	7.0	117
52	Radiosynthesis and biological evaluation of the M1 muscarinic acetylcholine receptor agonist ligand [¹¹ C]AF150(S). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 264-273.	1.0	9